FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124835126> ?p ?o ?g. }

• W2124835126 endingPage "101" @default.
• W2124835126 startingPage "91" @default.
• W2124835126 abstract "The purpose of this to evaluate in a phase I/II study the efficacy and toxicity of a multi-dose administration of 131I labeled CD22 monoclonal antibody (131I-MAb-LL2) in escalating dose cohorts administered to relapsed non-Hodgkin's lymphoma (NHL) patients. Twenty-one patients with relapsed NHL received one of four dose levels of 131-MAb-LL2 administered in a twice weekly pattern. Starting with dose level 2, the patients also received 20 mg of unlabeled LL2 prior to each radiolabeled dose administered. Previously stored autologous peripheral blood progenitors were reinfused in case of prolonged cytopenias. Patients could repeat the same treatment if they had stable disease or a response to the first therapy at 8 weeks, and had not received their peripheral blood progenitors with the first cycle. Combining all of the dose cohorts, there were 5 complete responses or complete responses (undetermined) and 2 partial responses for a total response rate of 7/21 (33%). There was no dose response effect with responses documented at all dose levels. Expected toxicities were hematopoietic, requiring stem cell re-infusion in 5 patients. Other toxicities included hypothyroidism in 3 patients, and human anti-mouse antibody formation (HAMA) in 4 patients. In conclusion, 131I-MAb-LL2, when administered in a multi-dose fashion with 20 mg unlabeled antibody pre-dosing, resulted in a response rate of 33% in heavily pre-treated NHL patients. Non-hematologic toxicities were mild and few in number. Further evaluation of this treatment is warranted and further dose escalation will be possible." @default.
• W2124835126 created "2016-06-24" @default.
• W2124835126 creator A5015628512 @default.
• W2124835126 creator A5017386283 @default.
• W2124835126 creator A5024168671 @default.
• W2124835126 creator A5057802088 @default.
• W2124835126 creator A5061471602 @default.
• W2124835126 creator A5061532811 @default.
• W2124835126 creator A5070384778 @default.
• W2124835126 creator A5072641295 @default.
• W2124835126 creator A5080373697 @default.
• W2124835126 creator A5082864167 @default.
• W2124835126 date "2000-01-01" @default.
• W2124835126 modified "2023-10-01" @default.
• W2124835126 title "Phase I/II Trial of Multiple Dose¹³¹Iodine-MAb LL2 (CD22) in Patients with Recurrent Non-Hodgkin's Lymphoma" @default.
• W2124835126 cites W1484629663 @default.
• W2124835126 cites W1485533072 @default.
• W2124835126 cites W1557597732 @default.
• W2124835126 cites W1605164920 @default.
• W2124835126 cites W1849027585 @default.
• W2124835126 cites W1868627100 @default.
• W2124835126 cites W1915689252 @default.
• W2124835126 cites W1940470585 @default.
• W2124835126 cites W1974078366 @default.
• W2124835126 cites W1999591023 @default.
• W2124835126 cites W2033785962 @default.
• W2124835126 cites W2084493022 @default.
• W2124835126 cites W2117964879 @default.
• W2124835126 cites W2128997140 @default.
• W2124835126 cites W2179208207 @default.
• W2124835126 cites W2263814165 @default.
• W2124835126 cites W2302140131 @default.
• W2124835126 doi "https://doi.org/10.3109/10428190009060322" @default.
• W2124835126 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10811451" @default.
• W2124835126 hasPublicationYear "2000" @default.
• W2124835126 type Work @default.
• W2124835126 sameAs 2124835126 @default.
• W2124835126 citedByCount "66" @default.
• W2124835126 countsByYear W21248351262012 @default.
• W2124835126 countsByYear W21248351262013 @default.
• W2124835126 countsByYear W21248351262014 @default.
• W2124835126 countsByYear W21248351262015 @default.
• W2124835126 countsByYear W21248351262016 @default.
• W2124835126 countsByYear W21248351262017 @default.
• W2124835126 countsByYear W21248351262020 @default.
• W2124835126 countsByYear W21248351262023 @default.
• W2124835126 crossrefType "journal-article" @default.
• W2124835126 hasAuthorship W2124835126A5015628512 @default.
• W2124835126 hasAuthorship W2124835126A5017386283 @default.
• W2124835126 hasAuthorship W2124835126A5024168671 @default.
• W2124835126 hasAuthorship W2124835126A5057802088 @default.
• W2124835126 hasAuthorship W2124835126A5061471602 @default.
• W2124835126 hasAuthorship W2124835126A5061532811 @default.
• W2124835126 hasAuthorship W2124835126A5070384778 @default.
• W2124835126 hasAuthorship W2124835126A5072641295 @default.
• W2124835126 hasAuthorship W2124835126A5080373697 @default.
• W2124835126 hasAuthorship W2124835126A5082864167 @default.
• W2124835126 hasConcept C109159458 @default.
• W2124835126 hasConcept C126322002 @default.
• W2124835126 hasConcept C159654299 @default.
• W2124835126 hasConcept C203014093 @default.
• W2124835126 hasConcept C2776146153 @default.
• W2124835126 hasConcept C2779338263 @default.
• W2124835126 hasConcept C28328180 @default.
• W2124835126 hasConcept C29730261 @default.
• W2124835126 hasConcept C542903549 @default.
• W2124835126 hasConcept C54355233 @default.
• W2124835126 hasConcept C71924100 @default.
• W2124835126 hasConcept C86803240 @default.
• W2124835126 hasConcept C90924648 @default.
• W2124835126 hasConcept C98274493 @default.
• W2124835126 hasConceptScore W2124835126C109159458 @default.
• W2124835126 hasConceptScore W2124835126C126322002 @default.
• W2124835126 hasConceptScore W2124835126C159654299 @default.
• W2124835126 hasConceptScore W2124835126C203014093 @default.
• W2124835126 hasConceptScore W2124835126C2776146153 @default.
• W2124835126 hasConceptScore W2124835126C2779338263 @default.
• W2124835126 hasConceptScore W2124835126C28328180 @default.
• W2124835126 hasConceptScore W2124835126C29730261 @default.
• W2124835126 hasConceptScore W2124835126C542903549 @default.
• W2124835126 hasConceptScore W2124835126C54355233 @default.
• W2124835126 hasConceptScore W2124835126C71924100 @default.
• W2124835126 hasConceptScore W2124835126C86803240 @default.
• W2124835126 hasConceptScore W2124835126C90924648 @default.
• W2124835126 hasConceptScore W2124835126C98274493 @default.
• W2124835126 hasIssue "1-2" @default.
• W2124835126 hasLocation W21248351261 @default.
• W2124835126 hasLocation W21248351262 @default.
• W2124835126 hasOpenAccess W2124835126 @default.
• W2124835126 hasPrimaryLocation W21248351261 @default.
• W2124835126 hasRelatedWork W1971628265 @default.
• W2124835126 hasRelatedWork W1972357268 @default.
• W2124835126 hasRelatedWork W1973774944 @default.
• W2124835126 hasRelatedWork W2093273184 @default.
• W2124835126 hasRelatedWork W2098645237 @default.
• W2124835126 hasRelatedWork W2159173527 @default.
• W2124835126 hasRelatedWork W2168323396 @default.
• W2124835126 hasRelatedWork W2178331071 @default.

• next